DoxorubicinPaclitaxelAntibiotics, AntineoplasticInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsTaxoidsCisplatinAntineoplastic AgentsCombined Modality TherapyCell Line, TumorAntineoplastic Agents, PhytogenicDrug Resistance, NeoplasmTreatment OutcomeChemotherapy, AdjuvantRemission InductionBreast NeoplasmsApoptosisDrug Administration ScheduleDisease-Free SurvivalCaspase 12CyclophosphamideTumor Suppressor Protein p53Survival AnalysisCarboplatinLung NeoplasmsNeoplasm StagingSurvival RateEtoposideNeoadjuvant TherapyFluorouracilHead and Neck NeoplasmsCarcinoma, Squamous CellVincristineCarcinoma, Non-Small-Cell LungVinblastineCardiomyopathiesDeoxycytidineIfosfamideDaunorubicinDose-Response Relationship, DrugCytarabineNeutropeniaPrognosisMitochondria, HeartDNA DamageLeukemia, Myeloid, AcuteNeoplasm Recurrence, LocalInfusions, IntravenousTumor Markers, BiologicalGene Expression Regulation, NeoplasticRNA, Small InterferingRNA, MessengerNeoplasm MetastasisSignal TransductionHeartOvarian NeoplasmsMyocardiumAdenocarcinomaTime FactorsRadiotherapy, AdjuvantMethotrexateNeoplasmsGranulocyte Colony-Stimulating FactorBridged CompoundsP-GlycoproteinKaplan-Meier EstimateTumor BurdenBleomycinEnzyme InductionChemoradiotherapyFollow-Up StudiesSalvage TherapyMitoxantroneEpirubicinLeukopeniaRadiotherapyRadiotherapy DosageAnthracyclinesPrecursor Cell Lymphoblastic Leukemia-LymphomaMaximum Tolerated DoseBone NeoplasmsDisease ProgressionDrug SynergismIdarubicinAntimetabolites, AntineoplasticXenograft Model Antitumor AssaysHypopharyngeal NeoplasmsTumor Necrosis Factor-alphaAntibodies, Monoclonal, HumanizedLaryngectomyProspective StudiesNasopharyngeal NeoplasmsTransplantation, AutologousAntibodies, MonoclonalBrain NeoplasmsLeukemia, MyeloidMice, NudeTesticular NeoplasmsOrganoplatinum CompoundsPrednisone